JP2011055747A - Food or feed additive with effect of suppressing absorption of mycotoxin into body - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a food or feed additive with effect of suppressing the internal absorption of mycotoxin; to provide food or feed containing the additive; and to provide a method for suppressing the internal absorption of mycotoxin which is possibly mixed in food or feed. <P>SOLUTION: A composition containing low-methoxyl pectin and calcium salt is used as the food or feed additive for suppressing the internal absorption of mycotoxin. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to an additive for food or feed that has an effect of suppressing in vivo absorption of mycotoxins, and a food or feed containing the additive. The present invention also relates to a method for suppressing in vivo absorption of mycotoxins that may be present in food or feed.

  Mycotoxins are secondary metabolites produced by molds and are a general term for compounds harmful to humans and animals. It is known that many compounds and their analogs exist. Mycotoxin poisoning, in acute cases, presents with major symptoms of sudden diarrhea and liver dysfunction. In chronic cases, inflammation of the internal organs causes major symptoms of digestive disorders and respiratory diseases. Some mycotoxins may be highly mutagenic or cause decreased immune capacity. Deoxynivalenol and the like are listed as mycotoxins that are particularly frequently contaminated with grains.

  Deoxynivalenol (hereinafter abbreviated as DON) is a trichothecene mycotoxin produced mainly by Fusarium fungi (red mold), and is also referred to as vomitoxin or vomiting toxin. The main producers are Fusarium genus F.graminearum, F.culmorum, etc., which is one of the plant pathogens that cause red mold disease mainly in wheat and is the most widely used in cereals due to contamination in the field. Damage, especially corn and wheat DON contamination, is a global problem.

  Fumonisins are molds belonging to the genus Fusarium, F. verticillioides, F. It is a mycotoxin produced by moniliforme and F. proliferatum and is known as a mold toxin that contaminates cereals. In particular, there are many cases of fumonisin contamination of livestock feed, which is not acutely toxic, but as a long-term toxicity, it causes liver dysfunction and cardiac dysfunction to most domestic animals, and is also suspected to be mutagenic. In Japan, standard values are set only for feed, and there is no standard value for foods. Recently, attention has been focused on the teratogenicity related to the neural tube of newborns in countries and regions where processed corn is a staple food. This is a mold poison that needs attention in the future.

  Patulin is a mold toxin produced by molds such as Penicillium expansum and having lethal toxicity to various animals. Contamination to fruit juice is particularly serious, and contamination of patulin with apple juice has been reported in various countries, causing serious damage.

  As a conventional method for removing or detoxifying mycotoxins in foods and feeds, a method of sterilizing and reducing mycotoxin-producing bacteria per se using an agrochemical mainly composed of a bactericidal agent or an antibacterial agent is common. There is also a method of reducing the amount of mycotoxins contaminated with a mycotoxin biosynthesis inhibitor (Patent Document 1). However, these methods have problems such as environmental pollution caused by agricultural chemicals.

  On the other hand, for removal and detoxification of toxins in food and feed already contaminated with mycotoxins, a method using mycotoxin detoxification enzyme (Patent Document 2), a method of breeding mycotoxin detoxification bacteria such as Eubacterium, etc. (Patent Document 3). However, these methods require an environment in which special and expensive enzymes and bacteria are propagated, and are difficult to apply to many foods and feeds. Moreover, although the method of removing mycotoxin from feed using the mycotoxin adsorption agent which contains a fossil coral as a main component is established, the effect is limited (patent document 4).

JP 2009-167138 A JP-T-2001-521362 Special table 2008-520194 gazette JP 2007-174926 A

  The present invention relates to a method for reducing the effects of mycotoxins on a living body by suppressing the absorption of mycotoxins into the body when food or feed that may already be contaminated with mycotoxins is consumed. The purpose is to provide.

  In order to solve the above-mentioned problems, the present inventors have made extensive studies. When a composition containing low methoxy pectin and a calcium salt is allowed to coexist in a food or feed contaminated with mycotoxin, the mycotoxin is mixed with the above composition. It has been found that absorption and accumulation of mycotoxins in the body can be suppressed by being taken into the gel formed from the product and being stably confined within the gel.

The present invention has been developed based on such findings, and includes the following aspects:
(I) Food or feed additive for suppressing mycotoxin absorption in the body (I-1) For food for suppressing mycotoxin absorption in the body, comprising low methoxyl pectin and calcium salt Additive for feed.
(I-2) The food or feed additive described in (I-1), which contains a calcium salt in a proportion of 0.2 parts by mass or more with respect to 100 parts by mass of low methoxyl pectin.
(I-3) The food or feed additive according to (I-1) or (I-2), wherein the low methoxyl pectin is an amidated pectin.
(I-4) The food or feed according to any one of (I-1) to (I-3), wherein the mycotoxin is at least one selected from the group consisting of deoxynivalenol, fumonisin, and patulin Additive.

(II) Feed A feed containing the feed additive described in any one of (I-1) to (I-4) for the purpose of suppressing in vivo absorption of mycotoxins.

(III) Method for inhibiting absorption of mycotoxins in the body <Desc / Clms Page number 11> For a non-human animal, the feed additive according to any of (I-1) to (I-4) or (II) A method for suppressing mycotoxin absorption in the body, comprising orally administering a feed to be treated.

  According to the present invention, an additive for food or feed that can significantly suppress the absorption and accumulation of mycotoxins in the body when food or feed contaminated with mycotoxins is ingested, and the addition of the same Food or feed can be provided.

  For example, the food additive of the present invention containing low methoxy pectin and calcium salt can be used for, for example, jelly-like food (including confectionery) for infants and the elderly who are difficult to chew. Therefore, it is considered useful as a countermeasure against mycotoxins for high-risk individuals with low resistance to mycotoxins.

The time-dependent transition of the DON density | concentration in the serum of the mouse group which orally administered the formulation (Example 2) of this invention is shown (Experimental example 3). The time-dependent transition of the DON density | concentration in the serum of the mouse group which orally administered the formulation of the comparative example 1 is shown (Experimental example 3).

  The present invention is an additive for food or feed containing low methoxyl pectin (hereinafter referred to as “LM pectin”) and calcium salt as main components. Such an additive has the effect of capturing mycotoxins by forming a gel in the presence of water, and also stably trapping them inside the gel, and has the effect of suppressing absorption and accumulation of mycotoxins in the body based on such effects. Demonstrate. For this reason, the additive of the present invention is used for the purpose of suppressing the absorption and accumulation of mycotoxins in the body only for the mycotoxins that may be present in the food or feed, together with the food or feed.

  Here, “with food or feed” means not only when the additive is used in a state where it is mixed with food or feed, but also when it is taken in combination with food or feed; When ingesting food or feed; used to mean any aspect of ingesting additives immediately after ingesting food or feed.

  The LM pectin used in the present invention is D-galacturonic acid or D-galacturonic acid which is obtained by extracting the skin of a plant or the like with an acidic solution and methyl-esterified with a carboxyl group of D-galacturonic acid or D-caracturonic acid. It is a polysaccharide composed of a main chain composed of galacturonic acid methyl ester and a side chain composed mainly of neutral sugars such as arabinose and glucose. Lemon and lime are the most suitable sources of pectin, but orange, grapefruit and apple may be used.

  Pectin is known to form a gel by binding a free carboxyl group of D-galacturonic acid to a divalent cation, particularly calcium ion. Pectin is in a high methoxyl state with a degree of esterification of 50% or more in the crude extraction stage from the raw material. In this state, since there are too few free carboxyl groups and the gelation reaction is difficult to proceed, LM pectin with a reduced degree of methoxylation is widely distributed. In the present invention, since it is necessary to gel pectin with calcium ions, it is necessary that the pectin is reduced in methoxylation and the degree of methoxylation is 50% or less. Preferred is a pectin having a methoxylation degree of 10% or more and 40% or less.

  In order to reduce the degree of methoxylation, acid, enzyme treatment and ammonia treatment are generally carried out, and pectin is amidated during the ammonia treatment. In the present invention, both non-amidated amidated pectin and amidated amidated pectin can be used. As shown in the experimental examples to be described later, amidated pectin is preferably used because of its high mycotoxin uptake rate.

  These LM pectin is widely distributed as a food additive, and anyone can easily obtain it commercially. Commercially available products include, for example, Bistop [TM] D-2262 for non-amidated pectin and Bistop [TM] D-2264 for amidated pectin (both are San-Eigen F.F. Can be mentioned). Regardless of whether the form is granular, granular, or powder (including spray-dried powder), any form can be used.

  Examples of the calcium salt used in the present invention include calcium chloride, hydroxide, carbonate, bicarbonate, and organic acid salt. Examples of the organic acid include lactic acid, citric acid, pyruvic acid, ascorbic acid, malic acid, maleic acid and the like. Carbonate and lactate are preferable. Here, as calcium salts that are easily dissolved in water under neutral conditions, calcium chloride and hydroxide are calcium salts that are hardly soluble in water under neutral conditions but are readily soluble under acidic conditions. Examples of the salt include an organic acid salt such as calcium carbonate, hydrogen carbonate, or lactate. A carbonate is preferred.

  These calcium salts can be used in any form regardless of the form, but considering the solubility in water, it is preferable to have a powder or granular form. Such calcium salts are also readily available commercially.

  The additive of the present invention can be produced by mixing LM pectin and a calcium salt. Preferably, it is produced by mixing LM pectin and calcium salt so that they coexist in a solid state. In consideration of solubility in water, it is preferable to mix LM pectin and calcium salt in the form of granules or powder, respectively. Moreover, you may manufacture the formulation of a granule form by granulating the mixed LM pectin and calcium salt using a fluid bed granulator. Furthermore, it can also be used as a liquid preparation prepared by dissolving low methoxyl pectin and calcium salt in an aqueous solvent having a pH of 5 or more in advance.

  As a ratio of LM pectin blended in the additive of the present invention, 20 to 99% by mass can be usually mentioned. Preferably it is 30-95 mass%, More preferably, it is 50-97 mass%. Moreover, the ratio of the calcium salt in the additive of this invention can mention 0.1-5 mass% normally, Preferably it is 0.2-3 mass%, More preferably, it is 0.5-3 mass%. is there. The ratio of the calcium salt to 100 parts by mass of LM pectin in the additive of the present invention is not particularly limited as long as it forms a gel, but is usually 0.2 parts by mass or more, preferably 0.5-5. Part by mass, more preferably 1 to 3 parts by mass.

  The additive of the present invention may be composed of LM pectin and a calcium salt as described above, and may contain other components as long as the effects of the present invention are not hindered. Examples of such other components include monosaccharides and disaccharides such as glucose, fructose, maltose, sucrose, and lactose, and relatively low molecular weight polysaccharides such as oligosaccharides and dextrins.

  As described above, the additive of the present invention is used together with food or feed that may contain mycotoxins. Preferably, the additive of the present invention is used in a state of being blended with the food or feed so that it is orally administered together with the food or feed of interest.

  Thus, when the additive of the present invention is orally ingested together with food or feed, LM pectin and calcium ions react in the stomach to gel, and the gel contains mycotoxins mixed in the food or feed. Confine. As a result, absorption and accumulation of mycotoxins in the body can be suppressed.

  In this case, the ratio of the additive of the present invention to be used for food or feed is such that LM pectin is 0.5% by mass or more, preferably 1% in 100% by mass of the final food or feed to which the additive is added. % Or more, and more preferably 2% by mass or more. The upper limit is not particularly limited, but is usually about 10% by mass.

  Thus, LM pectin gels by reacting with calcium ions in the presence of water at a low pH of 4 or less. For this reason, it is preferable to select the calcium salt used for the preparation of the additive of the present invention according to the shape of the food or feed.

  When the food or feed has a solid form, any calcium salt can be used regardless of whether it is easily water-soluble or slightly water-soluble under neutral conditions. In this case, the food or feed (solid form) containing the additive of the present invention is gelled by the reaction of LM pectin and calcium ions in the presence of water in the stomach after ingestion. As a result, the gel The mycotoxins mixed in food or feed will be trapped inside.

  When the food or feed has a gel shape, any calcium salt can be used regardless of whether it is easily water-soluble or slightly water-soluble under neutral conditions. Preferably, it is a calcium salt that shows water solubility under the pH conditions of food or feed. In this case, the food or feed (gel form) containing the additive of the present invention is already in that state because the mycotoxins mixed in the food or feed are confined in the gel. And accumulation will be suppressed.

  When the food or feed is neutral or alkaline and has the form of an aqueous solution, it is preferable to use a calcium salt that is sparingly soluble in water under neutral or alkaline conditions and readily soluble in water under acidic conditions. In this case, the food or feed (aqueous solution) containing the additive of the present invention is gelled by the reaction of LM pectin and calcium ions in the presence of acidic gastric fluid in the stomach after oral ingestion. Mycotoxins mixed in food or feed will be trapped in the gel.

  In addition, when foods and feeds are produced using the additives, the risk of suffering contamination with mycotoxins when those foods and feeds are ingested can be reduced. The additive is suitable for the production of gel food or feed. For example, foods such as custard pudding, milk pudding and other puddings, jelly, bavaroa, gummy texture candy, yogurt, etc. Examples include desserts.

  The feed additive preferably has a solid form such as a granular form or a powder form, and these additives are usually blended in the solid form feed together with the feed, or Ingested by animals other than humans as feed. Examples of animals other than humans include herbivores such as cattle, horses, sheep, goats and pigs; domestic animals such as elephants, rhinoceros, deer, giraffes, hippopotamus, camels, deer and rabbits. And poultry such as chicken, duck and quail can be exemplified.

  When the feed additive is orally ingested by the animal together with the feed or as a feed, the LM pectin and calcium ions react to gel in the stomach of the animal and mix mycotoxins mixed in the feed. Capture and contain inside. Thus, absorption and accumulation of mycotoxins in the animal body are suppressed, and adverse effects due to mycotoxin exposure can be reduced.

  Hereinafter, the contents of the present invention will be specifically described using the following examples, comparative examples, and experimental examples. However, the present invention is not limited to these.

Examples 1 to 3 and Comparative Example 1
Powdered amidated pectin Bistopt ™ D-2264 (degree of methoxylation: 35%, manufactured by San-Ei Gen FFI Co., Ltd.) and calcium lactate (manufactured by Sigma) The body was mixed to prepare a powdery preparation. Bistop [trademark] D-2264 alone (no emulsified calcium) was used as the preparation of Comparative Example 1.

Examples 4 to 6 and Comparative Example 2
Bistop [trademark] D-2262 (degree of methoxylation: 35%, manufactured by San-Ei Gen FFI Co., Ltd.) and calcium carbonate (manufactured by Sigma Co.), which are non-amidated pectin, in the amounts shown in Table 2 Powder mixing was performed to prepare a powdery preparation. Further, Bistop [trademark] D-2262 alone (no emulsified calcium) was used as the preparation of Comparative Example 2.

Experimental Example 1 Effect of suppressing dissolution of DON into external solution Using deoxynivalenol (DON) as mycotoxin, the mycotoxin uptake effect (effect of suppressing dissolution into external solution) of the additive of the present invention was evaluated.

(1) Experimental method Each powder formulation prepared in Examples 1 to 6 and Comparative Examples 1 and 2 was dissolved in ultrapure water so as to have the concentration (% by weight) shown in Table 3, and 100 ml thereof was dissolved at 5 μg / The sample was mixed with 15 ml of ultrapure water containing ml of DON (experimental samples 1-1 to 1-8). At this time, all the liquid samples were in the form of a solution having a slight viscosity.

  As a blank sample, a sample was prepared by mixing 100 ml of ultrapure water with 15 ml of ultrapure water containing 5 μg / ml DON. This solution became a solution having almost no stickiness.

  To each of these, 35 ml of 100 mM citrate buffer (pH 3) was added and stirred, and then 1500 ml of water was added thereto, and the mixture was allowed to stand at 37 ° C. overnight with gentle stirring. Experimental samples 1-1 to 1-6 gradually solidified immediately after the addition of citric acid, and became a gentle gel when left at 37 ° C. for a whole day and night. On the other hand, the experimental samples 1-7 and 1-8 and the blank sample did not gel.

  Next, DON liberated in the aqueous phase is quantified using the immunoenzyme measurement method (ELISA method) described below, and the free DON fraction (%) is calculated from the obtained DON amount based on the following formula. did.

<Immunoenzyme measurement method (ELISA method)>
DON / NIV (deoxynivalenol / nivalenol) antibody (obtained from Dr. Maragos of National Center for Agricultural Utilization Research, USA) 0.2M phosphate buffered saline (PBS) (manufactured by Wako Pure Chemical Industries, Ltd.) The antibody was prepared by diluting 2000 times.

  100 μl of this antibody was dispensed into each well of a 96-well plastic plate and allowed to stand at 4 ° C. for 18 hours. The plate after standing was washed 4 times with a washing solution (100 ml of 0.2 M PBS solution to which 900 ml of ultrapure water and 0.5 ml of Tween 20 (manufactured by Wako Pure Chemical Industries, Ltd.) were added to make 1 L). To this, 250 μl of 1% polyvinyl alcohol solution (manufactured by Tokyo Chemical Industry Co., Ltd.) was dispensed and allowed to stand for 30 minutes. This was further washed 4 times with a washing solution, and the plate was coated with DON / NIV antibody.

  Mix 75 µl of DON horseradish peroxidase (hereinafter referred to as DON-HRP) (manufactured by Wako Pure Chemical Industries, Ltd.) 75 µl diluted 10000 times with PBS containing 1% fetal bovine serum (BSA). Then, 100 μl of this mixed solution was dispensed onto the DON / NIV antibody-coated plate prepared above. To this, 100 μl of peroxidase chromogenic substrate (TMB substrate) (BD Biosciences) was dispensed and allowed to stand in the dark for 15 minutes, and then 100 ml of 2N sulfuric acid was dispensed, and the absorbance at 490 nm of this solution was measured. It was measured.

  The amount of DON in the experimental sample was calculated from a standard calibration curve. The standard calibration curve was prepared by diluting 1 ppm DON standard (manufactured by Wako Pure Chemical Industries, Ltd.) into 4 stages of 250 ppb, 62.5 ppb, 15.6 ppb, and 3.9 ppb using PBS instead of the experimental sample. This was prepared by coloring in the same manner as described above.

(2) Experimental results The results are shown in Table 3.

  Experimental samples 1-7 and 1-8 using low methoxyl pectin powder alone have a free DON fraction of 100%. From this, the added DON is the sample (experimental samples 1-7 and 1-8). It can be seen that it is not taken in and released to the outside as it is. On the other hand, in the experimental samples 1-1 to 1-6 prepared using the preparations of Examples 1 to 6 containing low methoxyl pectin and calcium, the added DON is taken into the gel formed from these samples. Thus, it was confirmed that DON was prevented from flowing out into the external liquid. In particular, remarkable effects were obtained in the experimental samples 1-1 to 1-3 using the preparations (Examples 1 to 3) amidated as low methoxyl pectin. Experimental samples 1-4 to 1-6 prepared using non-amidated pectin preparations (Examples 4 to 6) as low methoxyl pectin are the above-mentioned amidated pectin in experimental sample 1-6 having a high preparation content. Although the same inhibitory effect as the formulation which contains was acquired, when the formulation content decreased like experiment samples 1-5 and 1-4, the fall of the inhibitory effect was recognized. From these facts, it was found that a superior DON uptake effect can be obtained by using low methoxyl pectin as a low methoxyl pectin rather than a non-amidated product.

Experimental Example 2 Effect of inhibiting elution of fumonisin B1 and patulin into the external solution Using fumonisin B1 and patulin as mycotoxins, the mycotoxin uptake effect of the additive of the present invention (elution inhibiting effect on the external solution) was evaluated.

(1) Experimental method The powder preparations of Examples 1 to 3 and Comparative Example 1 were dissolved in ultrapure water so as to have the concentrations (mass%) shown in Table 4, and 100 ml of them were mixed with 5 μg / ml of fumonisin B1 and patulin. The sample was mixed with 15 ml of ultrapure water containing (experimental samples 2-1 to 2-4). At this time, all the liquid samples were in the form of a solution having a slight viscosity. As a blank sample, a sample prepared by mixing 100 ml of ultrapure water with 15 ml of ultrapure water containing 5 μg / ml fumonisin B1 and patulin was prepared. This solution became a solution having almost no stickiness.

  To each of them, 35 ml of 100 mM citrate buffer (pH 3) was added and gently mixed. To this, 1500 ml of water was added and allowed to stand at 37 ° C. for 24 hours with gentle stirring. Experimental samples 2-1 to 2-4 were gradually immobilized immediately after the addition of the citrate buffer, and after leaving at 37 ° C. for 24 hours, they became a gentle gel. On the other hand, the blank sample did not gel.

  Next, the amounts of fumonisin B1 and patulin liberated in the aqueous phase (the amount of mycotoxin) were quantified by LC / MS / MS under the following conditions. The value calculated based on the following formula from the amount of mycotoxins thus obtained was defined as the free mycotoxin fraction (%).

<LC / MS / MS method>
Fumonisin B1 and patulin were quantified using the 1100 series HPLC system (manufactured by Agilent) and the Quattro Ultima LC / MS / MS system (Waters) under the following conditions.

(1) Fumonisin B1
Column: Agilent Zorbax Extended C18
(5mm, 150 x 2.1mm) (manufactured by Agilent)
Mobile phase: 0.1% formic acid (in 1.0 mM ammonium acetate) + acetonitrile However, acetonitrile is gradient from 20% to 90% in 5 minutes and then held for 5 minutes Column temperature: 40 ° C
Injection volume: 10ml
Flow rate: 200ml / min
MS / MS condition: ESI positive mode
722> 352 (quantitative ions)
722> 334 (qualitative ions).

(2) Patulin column: Waters XTerra MS C18
(3.5mm, 100x2.1mm id) (manufactured by Waters)
Mobile phase: 2 mM ammonium acetate solution + acetonitrile However, acetonitrile is from 3% to 95% in 14 minutes Gradient column temperature: 40 ° C
Injection volume: 10ml
Flow rate: 200ml / min
MS / MS condition: ESI negative mode
153> 109 (quantitative ions)
153> 81 (qualitative ions).

(2) The experimental results are shown in Table 4.

  In the experimental samples 2-1 to 2-3 using the preparations of Examples 1 to 3, the free mycotoxin fraction after being allowed to stand at 37 ° C. for 24 hours was significantly suppressed as in the case of DON. It was confirmed that mycotoxins such as B1 and patulin were incorporated into the gel formed from the preparation of the present invention, and the outflow to the outside was suppressed.

  From the above Experimental Examples 1 and 2, it was confirmed that the gel formed from the preparation of the present invention containing low methoxy pectin and calcium salt has an action of taking in mycotoxins and suppressing outflow to the outside.

Experimental Example 3 Change in blood concentration of DON From the results of Experimental Examples 1 and 2, it was found that the gel formed from the preparation containing low methoxy pectin and calcium salt took up mycotoxins and confined them inside. Therefore, here, the in vivo behavior of mycotoxins contained in the gel was examined.

(1) Experimental method 1000 μg of deoxynivalenol (DON) was fractionated into a 1.5 ml microtube and dried. 0.01 g of the powder formulation of Example 2 and Comparative Example 1 was dissolved in 1 ml of ultrapure water and added to the above microtube. This was orally administered to B6C3F1 mice (assigned from Dr. Pestka of Michigan State University) (4 specimens in each test section) by 25 μl.

  Blood was collected over time from 15 minutes to 24 hours after administration, and the concentration of DON in the serum was measured. In addition, 24 hours after administration, the liver was removed from the mouse, and the DON concentration in the liver was measured.

<Method for quantifying DON in serum>
The collected blood is dispensed into an Eppendorf tube, centrifuged at 14000 rpm for 10 minutes at 4 ° C., and the supernatant is dispensed into another Eppendorf tube. 240 μl of 0.2 M PBS is added to 60 μl of the obtained serum, and this is subjected to the immunoenzyme measurement method (ELISA method) described in Experimental Example 1 to quantify the DON concentration in the serum.

<Method for quantifying DON in liver>
The removed liver is homogenized with a mixer, diluted 10-fold with 0.2 M PBS, boiled at 100 ° C. for 5 minutes, solids are precipitated by centrifugation, and the supernatant is collected. This is subjected to the immunoenzyme measurement method (ELISA method) described in Experimental Example 1 to quantify the DON concentration in the liver.

(2) Experimental results FIG. 1 shows the time course of serum DON concentration when the preparation of Example 2 was orally administered, and FIG. 1 shows the time course of serum DON concentration when the preparation of Comparative Example 1 was orally administered. It is shown in 2. Table 5 shows the DON concentration in the liver 24 hours after administration.

  DON is known to be absorbed from the stomach in a relatively short time immediately after oral administration. It was confirmed that the DON concentration in the serum of mice administered orally with the preparation of Comparative Example 1 reached the maximum (about 2200 ppb) in 15 minutes after administration, and then gradually decreased over time (FIG. 2). . On the other hand, the DON concentration in the serum of the mice orally administered with the preparation of Example 2 increased only to about 500 ppb 15 minutes after oral administration (1/4 or less in the case of Comparative Example 1), and immediately decreased thereafter. (FIG. 1). In addition, the DON concentration in the liver 24 hours after oral administration was lower than that in the mouse orally administered with the preparation of Comparative Example 1, and the DON concentration in the liver of the mouse orally administered with the preparation of Example 2 was low. The preparation of the present invention containing a calcium salt has an effect of suppressing the absorption and accumulation of mycotoxins in the body by suppressing the release of the mycotoxins in the gel formed from the preparations and releasing them to the outside. Was confirmed. In this sense, it can be said that the preparation of the present invention containing low methoxy pectin and calcium salt has an effect of reducing the expression of toxicity of mycotoxins.

Claims (6)

A food or feed additive for suppressing in vivo absorption of mycotoxins, comprising low methoxyl pectin and a calcium salt. The food additive or feed additive according to claim 1, comprising a calcium salt in a proportion of 0.2 parts by mass or more with respect to 100 parts by mass of low methoxyl pectin. The food or feed additive according to claim 1 or 2, wherein the low methoxyl pectin is an amidated pectin. The food or feed additive according to any one of claims 1 to 3, wherein the mycotoxin is at least one selected from the group consisting of deoxynivalenol, fumonisin, and patulin. A feed comprising the feed additive according to any one of claims 1 to 4 for the purpose of suppressing in vivo absorption of mycotoxins. A method for suppressing mycotoxin absorption in the body, which comprises orally administering to a non-human animal the feed additive according to any one of claims 1 to 4 or the feed according to claim 5.

Images